ZA200705017B - Liposomal formulation of bortezomib (PS-341) - Google Patents

Liposomal formulation of bortezomib (PS-341)

Info

Publication number
ZA200705017B
ZA200705017B ZA200705017A ZA200705017A ZA200705017B ZA 200705017 B ZA200705017 B ZA 200705017B ZA 200705017 A ZA200705017 A ZA 200705017A ZA 200705017 A ZA200705017 A ZA 200705017A ZA 200705017 B ZA200705017 B ZA 200705017B
Authority
ZA
South Africa
Prior art keywords
bortezomib
liposomal formulation
liposomal
formulation
Prior art date
Application number
ZA200705017A
Other languages
English (en)
Inventor
Zalipsky Samuel
Martin Francis
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ZA200705017B publication Critical patent/ZA200705017B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200705017A 2004-11-05 2007-06-04 Liposomal formulation of bortezomib (PS-341) ZA200705017B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62521604P 2004-11-05 2004-11-05

Publications (1)

Publication Number Publication Date
ZA200705017B true ZA200705017B (en) 2008-09-25

Family

ID=35947260

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705017A ZA200705017B (en) 2004-11-05 2007-06-04 Liposomal formulation of bortezomib (PS-341)

Country Status (21)

Country Link
US (2) US20060159736A1 (xx)
EP (2) EP1807053A1 (xx)
JP (2) JP2008519041A (xx)
KR (2) KR20070085644A (xx)
CN (2) CN101094649A (xx)
AR (1) AR051759A1 (xx)
AU (2) AU2005304881A1 (xx)
BR (2) BRPI0517061A (xx)
CA (2) CA2586354A1 (xx)
CR (1) CR9168A (xx)
EA (1) EA200701005A1 (xx)
IL (1) IL182967A0 (xx)
MX (2) MX2007005497A (xx)
NI (1) NI200700120A (xx)
NO (1) NO20072830L (xx)
NZ (2) NZ554950A (xx)
PE (1) PE20061135A1 (xx)
TW (1) TW200618820A (xx)
UY (1) UY29191A1 (xx)
WO (2) WO2006052733A1 (xx)
ZA (1) ZA200705017B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
WO2009047639A2 (en) * 2007-07-23 2009-04-16 Keimyung University Industry Academic Cooperation Foundation Epicatechin deficient green tea
EA028622B1 (ru) * 2007-08-06 2017-12-29 Милленниум Фармасьютикалз, Инк. Ингибиторы протеасом
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009026430A2 (en) * 2007-08-21 2009-02-26 Alza Corporation Liposome formulations of boronic acid compounds
EA201070296A1 (ru) * 2007-08-21 2010-08-30 Алза Корпорейшн Липосомные композиции для введения in vivo соединений бороновой кислоты
CN107266482A (zh) 2008-06-17 2017-10-20 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
KR100918776B1 (ko) * 2009-04-20 2009-09-24 계명대학교 산학협력단 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물
EP2323628B1 (en) * 2008-08-13 2022-04-13 California Institute of Technology Carrier nanoparticles and related compositions, methods and systems
NZ602392A (en) * 2010-03-18 2014-03-28 Innopharma Inc Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
IT1403157B1 (it) 2010-12-01 2013-10-04 Elbi Int Spa Macchina lavatrice con rilevazione delle vibrazioni della vasca o camera di lavaggio.
EP2680822B1 (en) * 2011-03-02 2022-02-23 Sensulin, LLC Vesicle compositions
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
CA2894846A1 (en) 2012-12-12 2014-06-19 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
WO2015002078A1 (ja) 2013-07-03 2015-01-08 日本化薬株式会社 ボロン酸化合物の新規製剤
WO2015117136A1 (en) * 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
SI3140310T1 (sl) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli in njihova uporaba
JP6672176B2 (ja) 2014-05-19 2020-03-25 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
CA2949517A1 (en) 2014-05-20 2015-11-26 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6715265B2 (ja) * 2015-05-04 2020-07-01 フェルザンティス アーゲーＶｅｒｓａｎｔｉｓ Ａｇ 膜内外ｐＨ勾配ベシクルを調製する方法
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
EP3795609B1 (en) 2015-07-01 2024-04-03 California Institute of Technology Cationic mucic acid polymer-based delivery systems
CN104958768A (zh) * 2015-07-17 2015-10-07 中国科学院长春应用化学研究所 一种葡聚糖-硼替佐米键合药及其制备方法
WO2017031084A1 (en) * 2015-08-14 2017-02-23 The Regents Of The University Of California Poly(vinyl alcohol) nanocarriers
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US10583083B1 (en) * 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US20200261596A1 (en) 2016-10-20 2020-08-20 Pfizer Inc. Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
JP6974670B2 (ja) * 2017-07-24 2021-12-01 ファルモサ バイオファーマ インコーポレイテッド 弱酸性薬物を含むリポソーム組成物およびその使用
EP3694864A4 (en) 2017-10-11 2021-10-13 Qpex Biopharma, Inc. BORONIC ACID DERIVATIVES AND THEIR SYNTHESIS
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN110540547A (zh) 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
CN109045272A (zh) * 2018-08-01 2018-12-21 厦门市壳聚糖生物科技有限公司 一种硼替佐米磷脂复合物及其制备方法与应用
KR20210149157A (ko) * 2019-05-14 2021-12-08 파모사 바이오팜 인코포레이티드 약산성 약물의 약제학적 조성물 및 투여 방법
US20220362268A1 (en) * 2019-10-07 2022-11-17 Cornell University Antimicrobial and antiviral effects of c2-c7 alkyl boronic acids
WO2022182993A1 (en) * 2021-02-25 2022-09-01 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN112915094A (zh) * 2021-03-26 2021-06-08 东南大学 一种硼替佐米脂质体制剂的制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5047245A (en) * 1985-07-26 1991-09-10 The Liposome Company, Inc. Novel composition for targeting, storing and loading of liposomes
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
WO1992002244A1 (en) * 1990-07-31 1992-02-20 The Liposome Company, Inc. Accumulation of amino acids and peptides into liposomes
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
AU5557796A (en) * 1995-04-18 1996-11-07 Dehlinger, Peter J. Liposome drug-loading method and composition
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6224903B1 (en) * 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
WO1998016201A1 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
CA2269758C (en) * 1996-10-22 2008-01-08 Hermes Biosciences, Inc. Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6051251A (en) * 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
WO2000023052A1 (en) * 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
DE60026030T2 (de) * 1999-07-14 2006-08-10 Alza Corp., Mountain View Neutrales lipopolymer und liposomale zusammensetzungen daraus
WO2001035966A1 (en) * 1999-11-19 2001-05-25 Topgene, Inc. Boron compounds and complexes as anti-inflammatory agents
WO2002059131A1 (en) * 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
EP1565193B1 (en) * 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions for treating cancer using proteasome inhibitor PS-341

Also Published As

Publication number Publication date
KR20070085644A (ko) 2007-08-27
CN101094648A (zh) 2007-12-26
AR051759A1 (es) 2007-02-07
AU2005304880A1 (en) 2006-05-18
NZ554951A (en) 2010-12-24
MX2007005497A (es) 2007-09-21
EA200701005A1 (ru) 2007-10-26
EP1807053A1 (en) 2007-07-18
CN101094649A (zh) 2007-12-26
KR20070085642A (ko) 2007-08-27
CA2586348A1 (en) 2006-05-18
WO2006052734A1 (en) 2006-05-18
AU2005304881A1 (en) 2006-05-18
JP2008519041A (ja) 2008-06-05
UY29191A1 (es) 2006-01-31
EP1807052A1 (en) 2007-07-18
JP2008519040A (ja) 2008-06-05
IL182967A0 (en) 2007-08-19
WO2006052733A1 (en) 2006-05-18
NI200700120A (es) 2008-05-15
CR9168A (es) 2008-11-24
NZ554950A (en) 2010-12-24
BRPI0517668A (pt) 2008-10-14
PE20061135A1 (es) 2006-10-20
US20060159736A1 (en) 2006-07-20
MX2007005499A (es) 2007-09-21
NO20072830L (no) 2007-07-24
TW200618820A (en) 2006-06-16
BRPI0517061A (pt) 2008-09-30
CA2586354A1 (en) 2006-05-18
US20060153907A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
ZA200705017B (en) Liposomal formulation of bortezomib (PS-341)
HK1164320A1 (en) Synthesis of bortezomib
IL178889A0 (en) Spot-on formulation useful for cosmetology and dermatology
IL246171B (en) Processes for the preparation of peptide-based compounds
IL238308B (en) Pharmaceutical preparations containing azalastine
PL1817048T3 (pl) Stabilne preparaty peptydów insulinotropowych
IL173808A0 (en) Pharmaceutical liposomal formulations
IL176988A0 (en) Pharmaceutical compositions containing amino alcohol compounds
EP1804823A4 (en) NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
HK1113311A1 (en) Skin preparation for external use
IL182950A0 (en) Liposomal formulation for oral administration of glutathione (reduced)
HK1109332A1 (zh) 藻毒素的經皮給藥
EP1768685A4 (en) COSMETIC COMPOSITIONS COMPRISING RHODIOLA ROSEA AND METHODS THEREOF
IL183986A0 (en) Pharmaceutical compounds and compositions
EP1762216A4 (en) COMPOSITION FOR COSMETIC PREPARATION AND COSMETIC PREPARATION
GB0423565D0 (en) Formulation
GB0316206D0 (en) Pharmaceutical formulation
GB0412530D0 (en) Formulation
HK1105358A1 (en) Solid pharmaceutical formulation
EP1740198A4 (en) ANTI-AGING EFFECT OF SUBSTANCE P
GB0425327D0 (en) Presentation of cosmetics
GB0410028D0 (en) Pharmaceutical formulation of apomorphine
GB0412882D0 (en) New formulation of eletriptan
GB0310881D0 (en) Pharmaceutical formulation
GB0418270D0 (en) Pharmaceutical formulation